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Overproduction of nitric oxide (NO) is thought to be a key mediator of the vascular dysfunction and severe
hypotension in patients with endotoxaemia and septic shock. The contribution of NO produced directly in the
vasculature by endothelial cells to the hypotension seen in these conditions, vs. the broader systemic increase
in NO, is unclear. To determine the speciﬁc role of endothelium derived NO in lipopolysaccharide (LPS)-induced
vascular dysfunctionwe administered LPS tomice deﬁcient in endothelial cell tetrahydrobiopterin (BH4), the es-
sential co-factor for NO production by NOS enzymes. Mice deﬁcient in endothelial BH4 production, through loss
of the essential biosynthesis enzyme Gch1 (Gch1ﬂ/ﬂTie2cre mice) received a 24 hour challenge with LPS or saline
control. In vivo LPS treatment increased vascular GTP cyclohydrolase and BH4 levels in aortas, lungs and hearts,
but this increase was signiﬁcantly attenuated in Gch1ﬂ/ﬂTie2cre mice, which were also partially protected from
the LPS-induced hypotension. In isometric tension studies, in vivo LPS treatment reduced the vasoconstriction re-
sponse and impaired endothelium-dependent and independent vasodilatations inmesenteric arteries fromwild-
type mice, but not in Gch1ﬂ/ﬂTie2cre mesenteric arteries. Ex vivo LPS treatment decreased vasoconstriction
response to phenylephrine in aortic rings from wild-type and not in Gch1ﬂ/ﬂTie2cre mice, even in the context
of signiﬁcant eNOS and iNOS upregulation. These data provide direct evidence that endothelial cell NO has a sig-
niﬁcant contribution to LPS-induced vascular dysfunction and hypotension andmay provide a novel therapeutic
target for the treatment of systemic inﬂammation and patients with septic shock.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Endotoxaemia is a leading cause of morbidity and mortality,
characterised by systemic inﬂammation, decreased peripheral vascular
resistance, microvascular leak and decreased cardiac output leading to
refractory hypotension [24]. High levels of nitric oxide (NO) production
by inducible nitric oxide synthase (iNOS, encoded by NOS2), which can
be induced by lipopolysaccharide (LPS), are believed to be a key media-
tor of these phenomena [21]. The synthesis of NO by all NOS isoforms
requires the cofactor tetrahydrobiopterin, BH4. Biosynthesis of BH4 is
catalysed by GTP cyclohydrolase I (GTPCH), a rate limiting enzyme for
de novo BH4 biosynthesis, which is encoded by Gch1. Increased circulat-
ing plasma biopterins and nitrite/nitrate have been reported in both an-
imals and patients with septic shock [3,10,14,15,29,31].
We have previously shown that Gch1 expression is a key determinant
of BH4 bioavailability, NOS regulation and thus NO generation in the vas-
culature of healthy mice [7,9,30]. In the vascular system, pro-
inﬂammatory stimuli have been shown to increase the synthesis of BH4
levels by up-regulating Gch1 mRNA and expression, that accompanies
up-regulation of iNOSmRNAandprotein in the endotheliumandvascular
smooth muscle [16,22,23]. Increased vascular iNOS-derived NO genera-
tion reduces vasocontractile response and causes hypotension which un-
derlies pathophysiology of endotoxaemia and septic shock. The relevant
contribution of endothelial NOS production to vascular dysregulation fol-
lowing systemic endotoxin exposure is unknown. Previous works have
also demonstrated the important role of endothelial NOS (eNOS) in the
pathogenesis of LPS-induced endotoxaemia and septic shock that eNOS
activity is the key determinant of iNOS expression and activity in murine
model of septic shock [8,32]. Indeed,micewith global eNOSdeﬁciency are
protected against LPS-induced vascular dysfunction and hypotension due
to loss of iNOS expression and activity [8,32].
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Systemic treatment of mice with a non-selective GTPCH inhibitor,
2,4-diamino-6-hydroxypyrimidine (DAHP) reduces BH4 levels, vascular
NOS-derived NO generation and reduces a degree of hypotension in an
experimental model of septic shock, despite no change in induction of
iNOS [3,26], suggesting a role forGch1 and BH4biosynthesis in the path-
ogenesis of septic shock. Furthermore, micewith global iNOS deﬁciency
are protected against LPS-induced vascular dysfunction and hypoten-
sion [20,32]. However, systemic administration of non-selective NOS
inhibitors has been shown to have inconsistent effects in both
experimental models and patients with septic shock [2,13,18]. These
observations highlight the need to better understand the mechanistic
role of the NOS enzymes in different cell types in the pathophysiology
of endotoxaemia and septic shock. It is not clear whether endothelial
cell-speciﬁc vs. systemic effects of NOS are important.
We have utilised a mouse model with endothelial cell-speciﬁc
deletion of BH4 biosynthesis to investigate the importance of endothe-
lial cell-derived NO production in the vascular and hemodynamic
responses to LPS-induced endotoxaemia.
2. Material and methods
2.1. Animals
All animal studies were conducted with ethical approval from the
Local Ethical Review Committee and in accordance with the UK Home
Ofﬁce regulations (Guidance on the Operation of Animals, Scientiﬁc
Procedures Act, 1986). Mice were housed in ventilated cages with a
12-hour light/dark cycle and controlled temperature (20–22 °C), and
fed normal chow and water ad libitum.
2.2. Gch1 conditional endothelial knockout mice
We have generated a Gch1 conditional knockout (ﬂoxed) allele
using Cre/loxP strategy. Exons 2 and 3 of Gch1, encoding for the active
site of GTPCH I, were ﬂanked by two loxP sites in a targeting construct
that was used to produceGch1ﬂ/ﬂmice after homologous recombination
in embryonic stem cells. Pups carrying the Gch1 ﬂoxed allele were then
back-crossed for 8 generations to the C57Bl/6J line. Once back-crossed
the resultant Gch1ﬂ/ﬂ animals were bred with Tie2cre transgenic mice
to produce Gch1ﬂ/ﬂTie2cre mice where Gch1 is deleted in endothelial
cells, generating a novel mouse model of endothelial cell-speciﬁc BH4
deﬁciency mouse [7]. The Tie2cre transgene is active in the female
germline, as such only male animals are used to establish breeding
pairs to maintain conditional expression. Mice were genotyped accord-
ing to the published protocol [7].
2.3. Non-invasive blood pressure measurement using tail-cuff method
Blood pressure in conscious wild-type and Gch1ﬂ/ﬂTie2cre mice was
measured using the Visitech BP-2000 tail-cuff plethysmography system.
Experiments were performed between the hours of 8:00 am and
12.00 pm. Twenty readings were taken per mouse of which the ﬁrst 5
readingswere discarded. The remaining15 readingswere used to calcu-
late themean systolic blood pressure and heart rate in eachmouse. Fol-
lowing 5 days of training, basal blood pressure and heart rate were
recorded for 3 consecutive days.
2.4. Administration of LPS
LPS (1 mg/kg body weight; Sigma-Aldrich, Gillingham, UK) or sterile
saline was administered in male wild-type and Gch1ﬂ/ﬂTie2cre mice
(16–22 week-old) via intraperitoneal (i.p.) route. Mice were injected be-
tween8:00 and 9:00 am for all studies to avoid diurnal variation in the re-
sponse to LPS. Mice were monitored throughout the study for adverse
effects. LPS administration is expected to cause a systemic inﬂammation
and hypotension, which may lead to hypothermia. To counteract this,
mice were maintained in a heated recovery cage and were given a
subcutaneous injection of saline in accordance with local ethical require-
ments. 24-hour post injection, mice were culled and tissues were collect-
ed. The dose of LPS used was not lethal in any experimental animals.
2.5. Determination of tissue tetrahydrobiopterin levels
BH4 and oxidised biopterins (BH2 and biopterin)were determined by
high-performance liquid chromatography (HPLC) followed by electro-
chemical and ﬂuorescence detection, respectively, following an
established protocol [4]. Brieﬂy, either a small piece of tissue (approxi-
mately 20mg)or awhole aortawas resuspended in ice-cold resuspension
buffer (50 mM phosphate-buffered saline, 1 mM dithioerythritol, 1 mM
EDTA, pH 7.4), and either homogenised (for tissues) or subjected to
three freeze–thaw cycles (for aortas). After centrifugation at 13,200 rpm
for 10 min at 4 °C, supernatant was removed and ice-cold acid precipita-
tion buffer (1 M phosphoric acid, 2 M trichloroacetic acid, 1 mM
dithioerythritol) was added. Following centrifugation at 13,200 rpm for
10 min at 4 °C, the supernatant was removed and injected onto the
HPLC system. Quantiﬁcation of BH4 and oxidised biopterinswas obtained
by comparison with external standards and normalised to protein con-
centration, determined by the BCA protein assay.
2.6. Isometric tension vasomotor studies
Vasomotor function was analysed using isometric tension studies in
a wire myograph (Multi-Myograph 610M, Danish Myo Technology,
Denmark). Brieﬂy, mice were culled by overdose of inhaled
isoﬂuraneand vascular rings were isolated from the thoracic aorta or
mesenteric arcades. The aortic rings or 2nd mesenteric arteries
(2 mm) were mounted on a wire myograph containing 5 ml of Krebs–
Henseleit buffer (KHB [in mmol/l]: NaCl 120, KCl 4.7, MgSO4 1.2,
KH2PO4 1.2, CaCl2 2.5, NaHCO3 25, glucose 5.5) at 37 °C, gassed with
95% O2/5% CO2. After allowing vessels to equilibrate for 30 min, the op-
timal tension was set (equivalent to 100 mm Hg). The vessel viability
was tested using 60 mM KCl. Concentration–response contraction
curves were established using cumulative half-log concentrations of
phenylephrine and U46619 in the presence or absence of 100 μM of
non-selective NOS inhibitor, L-NAME. Acetylcholine was used to stimu-
late endothelium-dependent vasodilatations in increasing cumulative
concentrations. Responses were expressed as a percentage of the pre-
constricted tension. The NO donor sodium nitroprusside (SNP) was
used to test endothelium-independent smooth muscle relaxation in
the presence of 100 μM L-NAME. All pharmacological drugs were pre-
incubated at least 20 min before the dose–response curves were deter-
mined. All drugs used were purchased from Sigma Chemical Company.
2.7. NOx determination
Lung homogenates and plasma were deproteinated in acid precipi-
tation buffer (1M phosphoric acid, 2M trichloroacetic acid), and the ni-
trite and nitrate content was quantiﬁed using a CLD88 NO analyser
(Ecophysics).
2.8. Western blot analysis
Western blots were performed with anti- GTPCH (a gift from S.
Gross, Cornell University New York), anti- iNOS (Abcam) and anti-
eNOS (BD Bioscience) antibodies in vascular tissues from wild-type
and Gch1ﬂ/ﬂTie2cre mice, using standard protocols.
2.9. Quantiﬁcation real-time RT-PCR
RNA were reserve transcribed using Superscript II (Life Technolo-
gies) according to standard protocols. 5 ng RNA equivalent cDNA was
used to perform real-time PCR using pre-designed TaqMan gene
70 S. Chuaiphichai et al. / Vascular Pharmacology 77 (2016) 69–79
expression assays (Life Technologies) using a BioRad CFX1000. Gene ex-
pression levels of mouse Gch1, Nos3 and Nos2 were normalised to the
housekeeping gene GAPDH using the Delta Ct method.
2.10. Statistical analysis
Data are expressed as mean ± standard error of the means and
analysed using GraphPad Prism version 5.0 (San Diego, USA). Compari-
sons betweenWTandGch1ﬂ/ﬂTie2creweremade by unpaired Student's t
test. Concentration–response curves were compared by two-way anal-
ysis of variance for repeated measurements followed by the Bonferroni
post-hoc test. A P-value of less than 0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Endothelial cell-targeted Gch1 deletion and BH4 deﬁciency attenuates
lipopolysaccharide-induced hypotension
We generated matched litters of Gch1ﬂ/ﬂTie2cre and Gch1ﬂ/ﬂmice by
crossing male Gch1ﬂ/ﬂTie2cre with female Gch1ﬂ/ﬂ mice (hereafter
referred as wild-type). Body weights between the groups were similar.
Blood pressure recordings were performed at 6 h and 24 h post LPS
administration (1 mg/kg i.p.). As was the case with our previous study
[7], baseline systolic blood pressure was signiﬁcantly increased in
Gch1ﬂ/ﬂTie2cre mice compared to wild-type littermates (105.8 ±
2.2 mm Hg versus 98.8 ± 2.0 mm Hg; P b 0.05). Six-hours after LPS
injection, systolic blood pressures were signiﬁcantly decreased in
both wild-type (80.1 ± 3.2 mm Hg; P b 0.01) and Gch1ﬂ/ﬂTie2cre
mice (95.3 ± 2.9 mm Hg; P b 0.05) (Fig. 1A), but with a signiﬁcantly
greater reduction in blood pressure in wild-type mice compared to
Gch1ﬂ/ﬂTie2cre mice (change in blood pressure, −20.8 ± 3.7 mm Hg
in wild-type versus −7.9 ± 4.2 mm Hg in Gch1ﬂ/ﬂTie2cre mice;
P b 0.05) (Fig. 1C). 24 h after LPS injection, Gch1ﬂ/ﬂTie2cre mice
remained signiﬁcantly less hypotensive than wild-type mice (change
in BP from baseline, −24.3 ± 3.0 mm Hg in wild-type versus
−12.5 ± 2.8 mm Hg in Gch1ﬂ/ﬂTie2cre mice; P b 0.05). Baseline heart
rate was similar between wild-type and Gch1ﬂ/ﬂTie2cre mice. Adminis-
tration of LPS signiﬁcantly reduced the heart rate of both genotypes at
6 h after injection (from 680 ± 12 bpm to 603 ± 17 bpm in wild-type
mice; from 694 ± 10 bpm to 598 ± 15 bpm in Gch1ﬂ/ﬂTie2cre mice)
and 24-hour post injection (592 ± 22 bpm in wild-type mice; 572 ±
Fig. 1. Effect of LPS on hemodynamic parameters in Gch1ﬂ/ﬂTie2cre mice. Mice from both genotypes either received a single dose of 1 mg/kg lipopolysaccharide (LPS) or saline control i.p.
and then underwent non-invasive tail-cuff recordings. A) Systolic blood pressure (mmHg), and B) heart rate (beat perminute)weremonitored at baseline, 6 and 24 h following injection.
The C) change in blood pressure and D) heart rate from baseline at the two timepoints was calculated (*P b 0.05, **P b 0.01 comparing genotypes, #P b 0.05, ##P b 0.01 comparing treat-
ment; n = 6 animals per group).
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20 bpm in Gch1ﬂ/ﬂTie2cre mice) (Fig. 1B and D), but this was not signif-
icantly different between genotypes. As expected, saline treatment had
no signiﬁcant effect on systolic blood pressures or heart rates in either
genotype (data not shown).
3.2. Increased vascular GTPCH and BH4 levels are attenuated in
Gch1ﬂ/ﬂTie2cre mice following LPS in vivo
Gene expression and western blot analysis of aortic extracts con-
ﬁrmed that basal vascularGch1 expression andGTPCHproteinwere sig-
niﬁcantly reduced in aortas from saline-treated Gch1ﬂ/ﬂTie2cre mice
when compared with saline-treated wild-type controls (Fig. 2A, B, and
C). Following LPS treatment, vascular Gch1 expression and GTPCH pro-
tein were increased in both wild-type and Gch1ﬂ/ﬂTie2cre mice, but
remained signiﬁcantly higher in wild-type mice (Fig. 2A, B, and C).
This was accompanied by a signiﬁcant decrease in vascular BH4 and
total biopterin levels in saline-treated Gch1ﬂ/ﬂTie2cre mice compared
to saline-treated wild-type mice (P b 0.05) (Fig. 2D). LPS treatment
also increased vascular BH4 and total biopterin levels. However, the in-
crease in vascular BH4 following LPS was signiﬁcantly attenuated when
endothelial BH4 production was absent in keeping with GTPCH protein
expression (P b 0.01) (Fig. 2D). Furthermore, vascular BH4 levels were
signiﬁcantly decreased by ≈70% in endothelial-denuded aortas from
wild-type mice following LPS treatment such that vascular BH4 was
no longer different between LPS treated wild-type and LPS treated
Gch1ﬂ/ﬂTie2cre mice. Removal of the endothelium has no signiﬁcant
effect on vascular BH4 levels in LPS treated Gch1ﬂ/ﬂTie2cre mice, sug-
gesting a complete excision of Gch1 gene with Tie2 in endothelial cells
in this model. This ﬁnding indicates signiﬁcant upregulation of vascular
GTPCH protein and thus BH4 biosynthesis in the endothelium following
LPS in vivo (Fig. 2E).
3.3. LPS treatment has no effect on vascular reactivity in aortas in both
wild-type and endothelial cell BH4 deﬁcient mice
We next determined the effect of LPS on vascular reactivity in con-
duit vessels. As was the case with our previous study [7], we found
that vasoconstriction in response to phenylephrinewas signiﬁcantly en-
hanced in Gch1ﬂ/ﬂTie2cre aortas compared to wild-type controls (P b
0.05). This difference was normalised in the presence of L-NAME
(Fig. 3A and B). Endothelium-dependent vasodilatation was minimally
impaired in Gch1ﬂ/ﬂTie2cre aortas compared to wild-type controls
(Fig. 3C). In the presence of H2O2 scavenger, catalase-polyethylene
glycol (PEG-catalase), endothelium-dependent vasodilatations were
signiﬁcantly inhibited in Gch1ﬂ/ﬂTie2cre aortas but unchanged in wild-
type aortas (Fig. 3D). There was no difference in endothelium-
independent vasodilatation to SNP between the genotypes (Fig. 3E).
Despite an increase in aortic GTPCH and BH4 levels following in vivo
LPS treatment, aortic vasoconstriction and vasodilatationwere unaffect-
ed by LPS treatment (Fig. 3A, B, C, D and E). Gene expression and west-
ern blot analysis demonstrated that LPS treatment had no signiﬁcant
effect on either aortic eNOS or iNOS expression or protein in either
Fig. 2. Vascular GTPCH and BH4 levels in aortas. A) Representative immunoblots showing aortic GTP cyclohydrolase (GTPCH) protein in wild-type and Gch1ﬂ/ﬂTie2cremice either treated
with saline control or 1 mg/kg lipopolysaccharide (LPS) for 24 h, with corresponding quantitative data in B), measured as percentage band density of β-tubulin (a loading control)
(*P b 0.05; comparing genotypes, #P b 0.05; comparing treatment; n = 6 aortas per group). C) Quantitative real-time PCR was used to quantify Gch1 gene expression in aortic extracts
(*P b 0.05; comparing genotypes, ##P b 0.01; comparing treatment; n = 4 aortas per group). D) Aortic BH4 and total biopterin levels, measured by HPLC, were signiﬁcantly reduced in
aortas from saline-treated Gch1ﬂ/ﬂTie2cremice compared to saline-treated wild-type littermates. Following 1mg/kg LPS treatment for 24 h, aortic BH4 and total biopterin levels were sig-
niﬁcantly elevated in both genotypes, but thedifference stillmaintained (*P b 0.05; ***P b 0.001 comparing genotypes, ##P b 0.01, ###P b 0.001 comparing treatment; n=6 to 8 aortas per
group). E) Vascular BH4 in endothelium-denuded aortas fromwild-type and Gch1ﬂ/ﬂTie2cremice following LPS in vivo (***P b 0.001 comparing genotypes, ###P b 0.001 comparing treat-
ment; n = 4 to 5 aortas per group).
72 S. Chuaiphichai et al. / Vascular Pharmacology 77 (2016) 69–79
Fig. 3. Effect of LPS on vascular reactivity in isolated aortas in vivo. Vasoconstriction in response to phenylephrine A) alone or B) in the presence of non-selective nitric oxide synthase in-
hibitor, L-NAME (100 mM) in aortic rings from wild-type and Gch1ﬂ/ﬂTie2cre either treated with saline control or 1 mg/kg lipopolysaccharide (LPS) for 24 h (*P b 0.05; comparing geno-
type; n = 6 to 8 animals per group). Endothelium-dependent vasodilatation to acetylcholine C) alone or D) in the presence of catalase-polyethylene glycol (PEG-catalase; 400 units/ml)
(*P b 0.05, **P b 0.01; comparing genotype; n = 4 to 6 animals per group). E) Endothelium-independent vasodilatation to sodium nitroprusside (SNP). F) Representative immunoblots
showing endothelial nitric oxide synthase (eNOS) and inducible NOS (iNOS) protein in aortas fromwild-type and Gch1ﬂ/ﬂTie2cre treatedwith either saline control or LPS in vivowith cor-
responding quantitative data in G and H), measured as percentage band density of β-tubulin (a loading control) (n= 6 aortas per group). I and J) Quantitative real-time PCRwas used to
quantify iNOS and eNOS gene expression in aortic extracts from wild-type and Gch1ﬂ/ﬂTie2cre either treated with saline control or LPS in vivo (n = 4 aortas per group).
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wild-type or Gch1ﬂ/ﬂTie2cremice (Fig. 3F, G, H, I and J). This ﬁnding sug-
gests that upregulation of vascular GTPCHand BH4 levels alone,without
alteration of NOS expression, has no signiﬁcant effect on vasomotor
function in conduit vessels following LPS treatment in vivo.
3.4. Increased vascular GTPCH, BH4 levels, andNO generation are attenuated
in tissues from Gch1ﬂ/ﬂTie2cre mice following LPS in vivo
To determine whether the dose of LPS given was sufﬁcient to cause
systemic alteration of Gch1 and NOS biology we analysed further endo-
thelial cell-rich tissues, such as lung and heart. As previously observed
BH4 and total biopterin levels were signiﬁcantly reduced in saline treat-
ed Gch1ﬂ/ﬂTie2cre mice when compared with saline treated wild-type
mice (Figs. 4A and B). Following LPS treatment, BH4 and total biopterin
levels were signiﬁcantly increased in both lung and heart tissues from
wild-type mice and slightly increased but not statistically signiﬁcant in
Gch1ﬂ/ﬂTie2cre mice (Fig. 4A and B). However this regulation of BH4
levels by LPS treatment was not seen in all tissues, as the liver showed
no signiﬁcant difference in BH4 levels between saline treated mice
and LPS treated mice in either wild-type or Gch1ﬂ/ﬂTie2cre mice
(Fig. 4C). However, dihydrobiopterin (BH2), which lacks NOS cofactor
activity, levels were signiﬁcantly increased in the liver from both wild-
type and Gch1ﬂ/ﬂTie2cre mice following LPS, such that the BH4/
(BH2 + biopterin) ratio was signiﬁcantly reduced in both wild-type
and Gch1ﬂ/ﬂTie2cre mice (Fig. S1). Furthermore, western blot analysis
of lung extracts conﬁrmed that LPS treatment caused a signiﬁcant
Fig. 4.BH4 levels, GTPCHprotein, andNOproduction in endotoxaemicmice. The levels of BH4 and total biopterin,measuredbyHPLC, inA) lung, B) heart, C) liver, andD)plasma fromwild-
type and Gch1ﬂ/ﬂTie2cre either treatedwith saline control or 1 mg/kg LPS for 24 h (*P b 0.05; **P b 0.01; ***P b 0.001 comparing genotypes, #P b 0.05, ##P b 0.01, ###P b 0.001 comparing
treatment; n = 4 to 6 animals per group). E) Representative immunoblots showing GTP cyclohydrolase (GTPCH) protein in lung homogenates from wild-type and Gch1ﬂ/ﬂTie2cre either
treated with saline control or LPS. Total nitrite and nitrate content, measured by NO analyser, in F) lung homogenates and G) plasma following saline control or LPS treatment in vivo
(*P b 0.05; comparing genotypes, #P b 0.05, comparing treatment; n = 4 to 6 animals per group).
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increase inGTPCHprotein inwild-type but unchanged inGch1ﬂ/ﬂTie2cre
mice (Fig. 4E). This was accompanied by a signiﬁcant increase in nitrite/
nitrate content in lung homogenates from LPS treated wild-type mice,
which was not detected in LPS treated Gch1ﬂ/ﬂTie2cre mice, indicating
that NOS activity is altered in the Gch1ﬂ/ﬂTie2cre mice (Fig. 4F).
In plasma, there was no detectable difference in basal BH4 and total
biopterin levels between saline-treated GCH1ﬂ/ﬂTie2cre and saline-
treated wild-type mice (Fig. 4D). Following LPS treatment, plasma
BH4 levels were unchanged, but plasma total biopterin levels were sig-
niﬁcantly increased in both wild-type and Gch1ﬂ/ﬂTie2cre mice, indicat-
ing an increase in oxidised biopterins (Fig. 4D). There was no signiﬁcant
difference in plasma nitrite/nitrate production between saline treated
mice and LPS treated mice in either wild-type or Gch1ﬂ/ﬂTie2cre mice
(Fig. 4G). These data indicated that the dose of LPS used, although sufﬁ-
cient to cause alteration in biopterin and NOS biology does not cause an
overwhelming NOS activation, asmay be observed with higher doses of
LPS [10].
3.5. Endothelial cell BH4 deﬁciency reduces LPS-induced vascular dysfunction
in resistance mesenteric arteries
To investigate the relationships between blood pressure and chang-
es in the resistance vasculature, mesenteric arteries fromwild-type and
Gch1ﬂ/ﬂTie2cre mice were harvested from LPS or saline-treated animals
Fig. 5. Effect of LPS on vascular reactivity in isolatedmesenteric arteries. Vascular reactivity in 2ndmesenteric arterieswas determined usingwiremyograph. Vasoconstriction in responses
to A) phenylephrine (PE) and C) U46619 was attenuated in 2nd order mesenteric arteries from lipopolysaccharide (LPS)-treated wild-type mice compared to saline-treated wild-type
mice. LPS treatment had no signiﬁcant effect on vasoconstriction in responses to either PE or U46619 in Gch1ﬂ/ﬂTie2cre mesenteric arteries (#P b 0.05, ##P b 0.01; n = 8 to 10 animals
per group). B and D) Vasoconstriction in responses to PE and U46619 were normalised in the presence of non-selective nitric oxide synthase inhibitor (100 mM; L-NAME). The effect
of LPS on E) endothelium-dependent vasodilatation to acetylcholine (Ach) and F) endothelium-independent vasodilatation to sodium nitroprusside (SNP) (#P b 0.05, ***P b 0.001;
n = 4 to 6 animals per group).
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24 h after injection. Inwild-typemesenteric arteries, LPS administration
signiﬁcantly attenuated the contractile response to the α-adrenoceptor
agonist phenylephrine (PE) (Fig. 5A; P b 0.05). This blunting of the con-
tractile response was prevented in the presence of L-NAME (Fig. 5B),
such that therewasno longer a signiﬁcant difference in vasoconstriction
between saline-treated and LPS-treated wild-type mice. This indicates
that increased NOS-derived NO is responsible for the decreased
vasoconstrictor response in mesenteric arteries from LPS-treated wild-
type. Similar ﬁndings were also observed when thromboxane A2
agonist U46619was used (Fig. 5C; P b 0.01), suggesting that the blunted
vasoconstrictor response was not due to speciﬁc alteration of receptor
signalling on vascular smoothmuscle cells. In contrast to these observa-
tions in wild-type mice, LPS treatment in Gch1ﬂ/ﬂTie2cre mice resulted
in no signiﬁcant alteration in vasoconstrictor response to either PE or
U46619 (Fig. 5A and B respectively). Furthermore, L-NAME treatment
had no effect on contractile response in LPS-treated Gch1ﬂ/ﬂTie2cre
mice (Fig. 5B and D).
In saline treated mice, endothelium-dependent vasodilatation in re-
sponse to acetylcholine was signiﬁcantly impaired in Gch1ﬂ/ﬂTie2cre
mesenteric arteries when compared with that in wild-type mesenteric
arteries (P b 0.001). Following LPS treatment, endothelium-dependent
vasodilatationwas signiﬁcantly impaired inwild-typemesenteric arter-
ies (P b 0.05), but unaltered in Gch1ﬂ/ﬂTie2cre mesenteric arteries, such
that endothelium-dependent vasodilatationwas no longer different be-
tween LPS treatedwild-type and LPS-treated Gch1ﬂ/ﬂTie2cremesenteric
arteries (Fig. 5E). Furthermore, LPS treatment signiﬁcantly reduced the
potency of endothelium-independent vasodilatation to SNP in wild-
type mesenteric arteries when compared to mesenteric arteries from
saline treated wild-type mice (Fig. 5F; P b 0.05). In contrast, LPS treat-
ment has no signiﬁcant effect on endothelium-independent vasodilata-
tion to SNP in Gch1ﬂ/ﬂTie2cre mesenteric arteries. This ﬁnding indicates
that endothelial cell BH4 regulates LPS-induced vascular dysfunction in
resistance arteries.
3.6. Endothelial cell BH4 deﬁciency prevents LPS-induced aortic dysfunction
ex vivo
To determine the effect of endothelial cell BH4 deﬁciency on vascu-
lar function in response to a higher dose of LPS and a clear induction of
vascular iNOS expression, isolated mouse aortic rings from wild-type
and Gch1ﬂ/ﬂTie2cre mice were incubated in Dulbecco's Modiﬁed Eagle
Medium (DMEM)with or without 1 μg/ml of LPS for 24 h. Following in-
cubation, GTPCH protein expression, BH4 and total biopterin levels
were signiﬁcantly increased in bothwild-type andGch1ﬂ/ﬂTie2cre aortas
(Fig. 6A, B and F). The induction of this pathwaywas signiﬁcantly great-
er in wild-type aortas, indicating the endothelial component of this re-
sponse. Western blot analysis demonstrated that eNOS and iNOS
protein expressions were also signiﬁcantly increased in both wild-
type and Gch1ﬂ/ﬂTie2cre aortas following LPS incubation (Fig. 6A, C, D
and E). Importantly, the induction of both eNOS and iNOS by LPS was
of a similar magnitude in both genotypes.
We next investigated the effect of endothelial cell BH4 deﬁciency on
vasomotor function in aortic rings treated with LPS ex vivo. Incubation
with LPS signiﬁcantly blunted vascular contractile function of wild-
type aortic rings in response to phenylephrine (PE) compared to
saline-treated wild-type controls. In the presence of L-NAME, vasocon-
striction was increased such that vasoconstriction was no longer differ-
ent between controls and LPS-treated aortas. In Gch1ﬂ/ﬂTie2cre aortas,
incubation with LPS had no signiﬁcant effect on vasocontractility com-
pared to saline-treated Gch1ﬂ/ﬂTie2cre aortas (Fig. 6G and H).
4. Discussion
In this study, we have demonstrated the speciﬁc role of endothelial
cell BH4-dependent NOS regulation in the pathogenesis of LPS-
induced vascular dysfunction and hypotension. The major ﬁndings of
this study are as follows. First, LPS treatment results in a signiﬁcant in-
crease in vascular GTPCH and BH4 levels in wild-type mice, but the
magnitude of this increase is attenuated in Gch1ﬂ/ﬂTie2cre mice,
demonstrating a speciﬁc endothelial cell component of this response.
Second, in vivo LPS treatment causes a reduction in vasoconstrictor
responses and an impairment of endothelium-dependent and indepen-
dent vasodilatation in mesenteric arteries from wild-type mice,
which are preserved in mesenteric arteries from Gch1ﬂ/ﬂTie2cre mice.
Third, ex vivo LPS treatment causes a NOS-mediated reduction in vaso-
constrictor responses in wild-type aortas, which again does not occur
in Gch1ﬂ/ﬂTie2cre aortas despite induction of iNOS and eNOS protein ex-
pression in both genotypes. Fourth, the lack of endothelial cell BH4 re-
sults in an attenuation of LPS-induced hypotension. Together these
ﬁndings demonstrate for the ﬁrst time that deﬁciency in endothelial
cell Gch1 and thus BH4 biosynthesis is alone sufﬁcient to protect against
LPS-induced vascular dysfunction and hypotension induced by the dose
of LPS used here, indicating a novel role of endothelial cell Gch1 and
BH4-dependentNOS regulation in the pathogenesis of LPS-induced vas-
cular dysfunction and hypotension.
A large body of evidence has demonstrated that administration of
bacterial LPS causes an increase in vascular Gch1mRNA, GTPCH protein
expression and BH4 levels in a coordinated manner with iNOS mRNA
such that vascular iNOS-derived NO is increased [3,21,26]. Consistent
with this, we found that in vivo LPS treatment causes an increase in vas-
cular GTPCH protein and BH4 levels in endothelial cell-rich tissues such
as aortas, lungs and hearts fromwild-typemice.We have previously re-
ported that the majority of vascular GTPCH and BH4 biosynthesis
(~70%) are contributed by the endothelium in healthy mice [7] and
human [11]. Thus, the endothelium may be a principal site of BH4 syn-
thesis following LPS treatment. Indeed, endothelial-denudation leads to
a reduction of vascular BH4 levels in aortas from LPS treated wild-type
but unaltered in LPS treated Gch1ﬂ/ﬂTie2cre mice, demonstrating
involvement of endothelial cells in GTPCH and BH4 biosynthesis in
LPS-induced endotoxaemia. However, as a signiﬁcant induction of BH4
is still observed in Gch1ﬂ/ﬂTie2cre aortic tissues, other cell types must
also upregulate BH4 production.
When a higher dose of LPS was applied to aortic rings ex vivo, an in-
crease in aortic iNOS protein in both wild-type and Gch1ﬂ/ﬂTie2cre mice
was observed. Interestingly, aortic eNOS expression was also markedly
increased in both genotypes following LPS ex vivo. This increased
eNOS expression may act as a protective mechanism in endotoxaemia
contributing to the maintenance of microcirculatory ﬂow. However, as
the ex vivo incubation system occurs in the absence of blood ﬂow and
the resulting sheer stress on the vessel wall care must be taken in ex-
trapolating these results to the in vivo situation. However, increased
eNOS expression has been documented inmesenteric arteries and skel-
etal muscle from an in vivo experimental model of LPS-induced
endotoxaemia [1,6]. In contrast, eNOS expression is decreased in vascu-
lar tissues from experimentalmodels of severe septic shock [5,12], indi-
cating that vascular eNOS expression is dependent on the severity of
disease induced by LPS. In the present study we found that the reduced
vasoconstrictor response is reversed by L-NAME in mesenteric arteries
fromwild-typemice following LPS in vivo, indicating that this ismediat-
ed by LPS-induced increases in tonic NOS-derived NO. In contrast to
wild-type mesenteric arteries, LPS treatment has no effect on vasocon-
strictor responses in mesenteric arteries from Gch1ﬂ/ﬂTie2cre mice.
Similar ﬁndings were also observed in conduit arteries (aortas) from
Gch1ﬂ/ﬂTie2cre mice pre-incubated with LPS ex vivo.
Interestingly, endothelium-dependent and independent vasodilata-
tions were impaired in mesenteric arteries fromwild-typemice follow-
ing LPS in vivo. This ﬁndingwas consistent with previous reports, which
had also described a decrease in sensitivity to NO following LPS treat-
ment, and this was shown to be iNOS dependent in the mesentery [5,
19]. In contrast, LPS had no signiﬁcant effect on either endothelium-
dependent or independent vasodilatation in Gch1ﬂ/ﬂTie2cre mice fol-
lowing LPS in vivo, indicating that the inability to induce endothelial
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cellGch1 expression, BH4 biosynthesis and thus NOS-derivedNO gener-
ation is likely to be the mechanism underlying the blunted decrease in
vasoconstrictor response and preserved endothelium-dependent and
independent vasodilatation in Gch1ﬂ/ﬂTie2cre mice. Previous works
have demonstrated that eNOS activity is the key determinant of iNOS
expression and activity in murine model of septic shock [8,32]. Consis-
tent with the previous reports, it is possible that deﬁciency in endothe-
lial cell BH4 reduces eNOS activity and thus iNOS expression and
activity, due to a loss of iNOS expression and/or BH4-dependent iNOS
activity in Gch1ﬂ/ﬂTie2cre mice following LPS treatment. In this study,
we demonstrated for the ﬁrst time that deﬁciency of BH4 in the endo-
thelial cell alone is sufﬁcient to protect from LPS-induced vascular dys-
function in mesenteric arteries in vivo.
Mice with global iNOS deﬁciency are protected against LPS-induced
vascular dysfunction and hypotension [5,20]. However, it is not clear
whether endothelial cell-speciﬁc vs. systemic effects of NOS are impor-
tant in the pathogenesis of LPS-induced endotoxaemia induced by high
doses of LPS or sepsis. In this study, we demonstrated for the ﬁrst time
that deﬁciency of BH4 in endothelial cells alone is protective against
LPS-induced hypotension. However, endotoxaemia and sepsis seen in
Fig. 6. Effect of ex vivo LPS treatment on wild-type and Gch1ﬂ/ﬂTie2cre aortas. A) Representative immunoblots showing GTP cyclohydrolase (GTPCH), endothelial nitric oxide synthase
(eNOS) protein in wild-type and Gch1ﬂ/ﬂTie2cre aortas incubated with either Dulbecco's Modiﬁed Eagle Medium (DMEM) alone or DMEM containing 1 μg/ml lipopolysaccharide (LPS)
for 24 h at 37 °C. B) Quantitative data, measured as percentage band density of β-tubulin, showing GTPCH, eNOS and iNOS protein in wild-type and GCH1ﬂ/ﬂTie2cre aortas incubated
with either saline control or LPS. C) Representative immunoblots with corresponding quantitative data below showing inducible NOS (iNOS) protein inwild-type and Gch1ﬂ/ﬂTie2cre aor-
tas incubatedwith either saline control or LPS. The identity of the bands obtained was conﬁrmed using control lysate from activated bonemarrow derivedmacrophage and iNOS−/− aor-
tas, and iNOS−/− aorta treatedwith LPS (*P b 0.05; n= 5 per groups). D) Tetrahydrobiopterin (BH4) and total biopterin levels, measured by HPLC, inwild-type and Gch1ﬂ/ﬂTie2cre aortas
incubatedwith either saline control or LPS for 24 h. Vascular reactivity in aortic ringswas determined usingwiremyograph. E) Vasoconstriction to phenylephrine (PE). F) Vasoconstriction
to PE in the presence of non-selective nitric oxide synthase inhibitor (L-NAME) (*P b 0.05 WT control vs.WT+ LPS, n = 5 to 6 aortas per group).
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critically ill patients and more severe animal models are typiﬁed by a
more profound decrease in blood pressure that causes organ failure
through underperfusion and death. Under these conditions iNOS is
expressed widely both locally within other vessel wall cells such as
smooth muscle cells, and in other non-vascular cells. In the data pre-
sented here the lack of endothelial cell Gch1 and reduced BH4 levels,
whilst providing signiﬁcant protection, is not sufﬁcient to entirely pre-
vent hypotension. The drop in blood pressure that is still observed in
Gch1ﬂ/ﬂTie2cre mice is likely to be induced by the overproduction of
iNOS-derived NO from non-endothelial cell sources. Indeed, we found
a signiﬁcant increase in vascular BH4 levels in endothelium-denuded
aortas from Gch1ﬂ/ﬂTie2cre mice following LPS in vivo, suggesting the
contribution of vascular GTPCH and BH4 levels from non-endothelial
cells in this model. Increased iNOS and Gch1 expression in vascular
smooth muscle cells has been reported to be associated with vascular
dysfunction and hypotension induced by LPS [16,23]. Consistent with
this idea, GTPCH feedback regulatory protein (GFRP) binding to
GTPCH is reported to cause allosteric negative feedback regulation in
the presence of excess BH4 production. The GFRP over expressing
mice demonstrate that limiting BH4 synthesis in smooth muscle cells
is partially protective from hypotension in the caecal ligation and punc-
ture (CLP)model of sepsis [28]. Interestingly, heart rate was signiﬁcant-
ly reduced in both wild-type and Gch1ﬂ/ﬂTie2cre mice following LPS
treatment, indicating LPSmediated physiological changes that are inde-
pendent of blood pressure. This ﬁnding is consistent with previous re-
ports both at low dose and high dose of LPS [25,27] where bradycardia
following LPS has been reported to be associated with a down-
regulation of β1-adrenoceptor level in the myocardium [27].
Although deﬁciency in endothelial cell Gch1 and BH4 protects
against LPS-induced vascular dysfunction and hypotension in
Gch1ﬂ/ﬂTie2cre mice using this non-lethal LPS dosing regimen, it is un-
known whether deﬁciency in endothelial cell Gch1 and BH4 biosynthe-
sis is protective against endotoxaemia caused by LPS at higher doses or
during septic shock in vivo. Investigation using vascular smooth muscle
cell-speciﬁc Gch1 deletion (e.g. SM22-cre mice) mice or knockout of
Gch1 in both endothelial cells and vascular smooth muscle cells may
provide an insight into understanding the role of Gch1 and BH4-
dependent NOS regulation in different vessel wall cells in the patho-
physiology of LPS-induced endotoxaemia and septic shock.
Systemic administration of non-selective NOS inhibitorsNG-methyl-
L-arginine (L-NMMA) has been shown to reduce plasma nitrite and ni-
trate and increase systemic vascular resistance and blood pressure in
humans with septic shock; it did not however improve mortality in
patients with septic shock [2,13,18]. Similarly, inhibition of NOS has
been shown to have inconsistent effect in experimental model of
endotoxaemia and septic shock. These observations indicate that the
role of NO in endotoxaemia and septic shock is complex. This is likely
due to the opposing local effects in the microcirculation. Reduced local
NO in organ microcirculation, due to NOS inhibitor treatment, may
lead to microcirculation hypoperfusion and organ damage in the
model of endotoxaemia and septic shock. In contrast, supplementation
of BH4 has been shown tomaintainmicrocirculation ﬂow and perfusion
and increase the rate of survival in ovinemodel of peritoneal sepsis [17].
Thus, achieving the right balance between reducing hypotension,whilst
maintaining organ perfusion in microcirculation may have therapeutic
potential in the treatment of septic patients and understanding the
cell type and enzymatic source of the NO contributing to both patholo-
gies may be key to achieving this.
5. Conclusions
We have demonstrated for the ﬁrst time that deﬁciency in endothe-
lial cell Gch1 and BH4 biosynthesis protects against LPS-induced
vascular dysfunction and hypotension. These ﬁndings suggest that en-
dothelial cell BH4-dependent NOS regulation plays a critical role in the
pathogenesis of this LPS-induced endotoxaemia. Thus, targeting endo-
thelial cell Gch1 and BH4 biosynthesis may provide a novel therapeutic
target for the treatment of circulatory collapse in patients with septic
shock.
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